Does the media refer more to IVVD or AVTX?

In the previous week, Invivyd had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Invivyd and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.92 beat Invivyd's score of 0.36 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CVAC or IVVD?

Invivyd has a consensus price target of $8.00, indicating a potential upside of 858.08%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings & valuation, CVAC or IVVD?

CureVac has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Invivyd $58.37M 4.22 -$52.49M -$0.33 N/A

Is CVAC or IVVD more profitable?

CureVac has a net margin of 199.92% compared to Invivyd's net margin of -183.90%. CureVac's return on equity of -23.03% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Invivyd -183.90% -59.73% -48.97%

Does the media favor IVVD or LXRX?

In the previous week, Invivyd had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Invivyd and 6 mentions for Lexicon Pharmaceuticals. Invivyd's average media sentiment score of 0.36 beat Lexicon Pharmaceuticals' score of -0.04 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer ABUS or IVVD?

In the previous week, Invivyd had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Invivyd and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.72 beat Invivyd's score of 0.36 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Invivyd 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, WVE or IVVD?

Invivyd has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WAVE Life Sciences $42.73M 21.67 -$204.38M -$1.09 N/A Invivyd $58.37M 4.22 -$52.49M -$0.33 N/A

Is WVE or IVVD more profitable?

Invivyd has a net margin of -183.90% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets WAVE Life Sciences -309.73% -50.36% -40.06% Invivyd -183.90% -59.73% -48.97%

Does the media refer more to WVE or IVVD?

In the previous week, Invivyd had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for Invivyd and 3 mentions for WAVE Life Sciences. Invivyd's average media sentiment score of 0.36 beat WAVE Life Sciences' score of -0.12 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Invivyd (IVVD) Competitors

$0.84 +0.03 (+3.86%)

As of 04:00 PM Eastern

Compare

IVVD vs. AVTX, CVAC, LXRX, ABUS, and WVE

Should you buy Invivyd stock or one of its competitors? Invivyd's main competitors and comparable companies include Avalo Therapeutics (AVTX), CureVac (CVAC), Lexicon Pharmaceuticals (LXRX), Arbutus Biopharma (ABUS), and WAVE Life Sciences (WVE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invivyd compare to Avalo Therapeutics?

Invivyd (NASDAQ:IVVD) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Invivyd has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$58.37M	4.22	-$52.49M	-$0.33	N/A
Avalo Therapeutics	$59K	17,270.68	-$78.26M	-$4.37	N/A

70.4% of Invivyd shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 858.08%. Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 137.37%. Given Invivyd's higher possible upside, equities research analysts plainly believe Invivyd is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Invivyd had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 8 mentions for Invivyd and 6 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.92 beat Invivyd's score of 0.36 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Avalo Therapeutics' return on equity of -58.03% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Invivyd has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Summary

Invivyd and Avalo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Invivyd compare to CureVac?

CureVac (NASDAQ:CVAC) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

CureVac has a net margin of 199.92% compared to Invivyd's net margin of -183.90%. CureVac's return on equity of -23.03% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Invivyd	-183.90%	-59.73%	-48.97%

17.3% of CureVac shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Invivyd had 8 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Invivyd and 0 mentions for CureVac. Invivyd's average media sentiment score of 0.36 beat CureVac's score of 0.00 indicating that Invivyd is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Invivyd	Neutral

Invivyd has a consensus price target of $8.00, indicating a potential upside of 858.08%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

CureVac has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Invivyd	$58.37M	4.22	-$52.49M	-$0.33	N/A

Summary

CureVac beats Invivyd on 9 of the 16 factors compared between the two stocks.

How does Invivyd compare to Lexicon Pharmaceuticals?

Invivyd (NASDAQ:IVVD) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Lexicon Pharmaceuticals has a net margin of -147.38% compared to Invivyd's net margin of -183.90%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Invivyd has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 858.08%. Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 101.33%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Invivyd had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Invivyd and 6 mentions for Lexicon Pharmaceuticals. Invivyd's average media sentiment score of 0.36 beat Lexicon Pharmaceuticals' score of -0.04 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

70.4% of Invivyd shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Invivyd. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$58.37M	4.22	-$52.49M	-$0.33	N/A
Lexicon Pharmaceuticals	$41.47M	24.25	-$50.34M	-$0.15	N/A

Summary

Lexicon Pharmaceuticals beats Invivyd on 9 of the 16 factors compared between the two stocks.

How does Invivyd compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential downside of 2.34%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 858.08%. Given Invivyd's higher probable upside, analysts plainly believe Invivyd is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Arbutus Biopharma has a net margin of 84.22% compared to Invivyd's net margin of -183.90%. Arbutus Biopharma's return on equity of 90.98% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Invivyd	-183.90%	-59.73%	-48.97%

Arbutus Biopharma has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	72.04	-$33.50M	$0.79	6.48
Invivyd	$58.37M	4.22	-$52.49M	-$0.33	N/A

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 12.3% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Invivyd had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Invivyd and 5 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.72 beat Invivyd's score of 0.36 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Invivyd	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arbutus Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Summary

Arbutus Biopharma beats Invivyd on 10 of the 16 factors compared between the two stocks.

How does Invivyd compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Invivyd (NASDAQ:IVVD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Invivyd has a net margin of -183.90% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Invivyd	-183.90%	-59.73%	-48.97%

Invivyd has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	21.67	-$204.38M	-$1.09	N/A
Invivyd	$58.37M	4.22	-$52.49M	-$0.33	N/A

In the previous week, Invivyd had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 8 mentions for Invivyd and 3 mentions for WAVE Life Sciences. Invivyd's average media sentiment score of 0.36 beat WAVE Life Sciences' score of -0.12 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

WAVE Life Sciences presently has a consensus price target of $22.31, suggesting a potential upside of 374.73%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 858.08%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than WAVE Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 12.3% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

WAVE Life Sciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Summary

Invivyd beats WAVE Life Sciences on 9 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$246.12M	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-2.53	12.72	273.59	25.45
Price / Sales	4.22	1,361.39	675.80	123.67
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	1.37	16.29	12.89	6.14
Net Income	-$52.49M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-7.23%	-1.38%	-0.33%	-1.47%
1 Month Performance	51.38%	11.06%	6.51%	2.47%
1 Year Performance	-19.71%	53.71%	25.19%	15.84%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	2.2411 of 5 stars	$0.84 +3.9%	$8.00 +858.1%	-21.9%	$246.12M	$58.37M	N/A	100	Gap Up
AVTX Avalo Therapeutics	3.2263 of 5 stars	$19.94 +3.5%	$45.10 +126.1%	+114.4%	$1.07B	$59K	N/A	40	News Coverage
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880
LXRX Lexicon Pharmaceuticals	1.6518 of 5 stars	$2.35 +1.2%	$4.55 +93.9%	+100.0%	$1.04B	$41.47M	N/A	140
ABUS Arbutus Biopharma	1.7116 of 5 stars	$5.20 0.0%	$5.00 -3.8%	+33.5%	$1.04B	$14.08M	6.63	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors

IVVD vs. AVTX, CVAC, LXRX, ABUS, and WVE

How does Invivyd compare to Avalo Therapeutics?

Summary

How does Invivyd compare to CureVac?

Summary

How does Invivyd compare to Lexicon Pharmaceuticals?

Summary

How does Invivyd compare to Arbutus Biopharma?

Summary

How does Invivyd compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invivyd (IVVD) Competitors

IVVD vs. AVTX, CVAC, LXRX, ABUS, and WVE

How does Invivyd compare to Avalo Therapeutics?

Which has preferable earnings & valuation, IVVD or AVTX?

Do institutionals & insiders hold more shares of IVVD or AVTX?

Do analysts recommend IVVD or AVTX?

Does the media refer more to IVVD or AVTX?

Is IVVD or AVTX more profitable?

Which has more volatility & risk, IVVD or AVTX?

Summary

How does Invivyd compare to CureVac?

Is CVAC or IVVD more profitable?

Do institutionals & insiders have more ownership in CVAC or IVVD?

Which has more risk & volatility, CVAC or IVVD?

Does the media prefer CVAC or IVVD?

Do analysts prefer CVAC or IVVD?

Which has higher earnings & valuation, CVAC or IVVD?

Summary

How does Invivyd compare to Lexicon Pharmaceuticals?

Is IVVD or LXRX more profitable?

Which has more risk & volatility, IVVD or LXRX?

Do analysts recommend IVVD or LXRX?

Does the media favor IVVD or LXRX?

Do institutionals and insiders hold more shares of IVVD or LXRX?

Which has preferable valuation and earnings, IVVD or LXRX?

Summary

How does Invivyd compare to Arbutus Biopharma?

Do analysts rate ABUS or IVVD?

Is ABUS or IVVD more profitable?

Which has preferable valuation & earnings, ABUS or IVVD?

Do insiders and institutionals hold more shares of ABUS or IVVD?

Does the media prefer ABUS or IVVD?

Which has more risk and volatility, ABUS or IVVD?

Summary

How does Invivyd compare to WAVE Life Sciences?

Is WVE or IVVD more profitable?

Which has better valuation & earnings, WVE or IVVD?

Does the media refer more to WVE or IVVD?

Do analysts prefer WVE or IVVD?

Do institutionals and insiders hold more shares of WVE or IVVD?

Which has more volatility and risk, WVE or IVVD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD vs. The Competition

Invivyd Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools